Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
SATELLITE SYMPOSIUM REPORT
4 března, 2021 6:26 pmOn 22 June 2017, a satellite symposium on „What is relevant for chronic myeloid leukaemia and Philadelphia-positive acute lymphoblastic leukaemia“...
DURABLE TREATMENT-FREE REMISSION (TFR) FOLLOWING FRONTLINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTFREEDOM 96-WK UPDATE
4 března, 2021 6:21 pmAuthor(s): David Ross, Tamas Masszi, María Teresa Gómez Casares, Andrzej Hellmann, Jesper Stentoft, Eibhlin Conneally, Valentin Garcia Gutierrez, Norbert Gattermann,...
DURABLE TREATMENT-FREE REMISSION (TFR) AFTER STOPPING SECOND-LINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTOP 96-WK UPDATE
4 března, 2021 6:18 pmAuthor(s): Timothy Hughes, Carla Boquimpani, Naoto Takahashi, Noam Benyamini, Nelma Cristina Clementino, Vasily Shuvaev, Sikander Ailawadhi, Jeffrey Lipton, Anna Turkina,...
5-YR RESULTS FROM THE PIVOTAL PHASE 2 PONATINIB PACE TRIAL: EFFICACY, SAFETY AND LANDMARK ANALYSIS IN HEAVILY PRETREATED PATIENTS (PTS) WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)
4 března, 2021 6:16 pmAuthor(s): Jorge E Cortes, Hagop M Kantarjian, Javier Pinilla-Ibarz, et al. Jorge E Cortes, Hagop M Kantarjian, Javier Pinilla-Ibarz, et...
ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10 -YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV
4 března, 2021 6:13 pmAuthor(s): Ruediger Hehlmann, Michael Lauseker, Susanne Saussele, et al. Abstract: S424 Session topic: 8. Chronic myeloid leukemia –...
DURABLE TREATMENT-FREE REMISSION (TFR) AFTER STOPPING SECOND-LINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTOP 96-WK UPDATE
4 března, 2021 6:11 pmAuthor(s): Timothy Hughes, Carla Boquimpani, Naoto Takahashi, et al. Abstract: P257 Session topic: 8. Chronic myeloid leukemia –...
IMPACT OF ARTERIAL THROMBOTIC EVENTS ON THE LONG-TERM OUTCOME OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS TREATED IN FIRST-LINE WITH NILOTINIB: AN ANALYSIS OF THE GIMEMA CML WORKING PARTY
4 března, 2021 6:09 pmAuthor(s): Gabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al. Abstract: P605 Session topic: 8. Chronic myeloid leukemia –...
Aktuality z EHA 2017 zaměřené na chronickou myeloidní leukemii
4 března, 2021 6:07 pmChronická myeloidní leukemie (CML) je klonální myeloproliferativní onemocnění, které představuje 15–25 % nově diagnostikovaných leukemií dospělého věku. Je příkladem onemocnění, u kterého...
POMALIDOMID IS MORE EFFECTIVE IN REAL CLINICAL PRACTICE THAN IN RANDOMIZED TRIAL – AN OBSERVATIONAL STUDY OF THE CZECH MYELOMA GROUP
4 března, 2021 6:05 pmAuthor(s): Ludek Pour, Lucie Brozova, Ivan Spicka, et al. Abstract: S 1290 Session topic: 14. Myeloma and other...
LENALIDOMIDE INDUCTION AND MAINTENANCE THERAPY FOR TRANSPLANT ELIGIBLE MYELOMA PATIENTS: RESULTS OF THE MYELOMA XI STUDY
4 března, 2021 6:03 pmAuthor(s): Charlotte Pawlyn, Faith Davies, David Cairns, et al. Abstract: S 781 Session topic: 14. Myeloma and other...